Language of Resource
Full Text Available
Open Access / OK to Reproduce
Did pandemic disruptions in filled buprenorphine and extended-release naltrexone prescriptions for opioid use disorder (OUD) differ by race and ethnicity or insurance status and payer type?
These findings suggest that the COVID-19 pandemic may have been associated with worsened disparities in filled buprenorphine and naltrexone prescriptions for OUD among members of racial and ethnic minority groups compared with White patients.
Cross-sectional study of 92% of US retail pharmacy claims of buprenorphine among 1 556 860 individuals and extended-release naltrexone among 127 506 individuals for OUD from May 2019 to June 2021